Paper
0
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Authors
Kris Kowdley,Stuart Gordon
K. Reddy,Lorenzo Rossaro,David Bernstein,Eric Lawitz,Mitchell Shiffman,Eugene Schiff,Reem Ghalib,Michael Ryan,Vinod Rustgi,Mario Chojkier,Hugo Vargas,Adrian Bisceglie,Paul Pockros,G. Subramanian,Di An,Vinay Pathak,Robert Gottlieb,Phillip Pang,William Symonds,John McHutchison,Andrew Ustianowski,David Pound
+22 authors
,Michael FriedPublished
Apr 11, 2014
Show more
Save
Tip0
TipSave
Abstract
High rates of sustained virologic response were observed among patients with hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor ledipasvir. This study examined 8 weeks of treatment with this regimen.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.